Teva Pharmaceutical launched a generic version of VESIcare (solifenacin succinate) tablets, 5 mg and 10 mg, in the U.S.
- Indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
Link to Statement: Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.